Kuros Biosciences stock analysis
Kuros Biosciences (0RHR) Share Price & Analysis
0RHR Stock Chart & Stats
- Day’s Range
- CHF 19.41 - CHF 19.54
- 52-Week Range
- CHF 16.46 - CHF 32.48
- Previous Close
- CHF 19.28
- Volume
- N/A
- Average Volume (3M)
- 11.67K
- Market Cap
- CHF 771.84M
- Enterprise Value
- CHF 776.03M
- Total Cash (Recent Filing)
- CHF 7.85M
- Total Debt (Recent Filing)
- CHF 11.01M
- Price to Earnings (P/E)
- 107.1
- Beta
- 0.98
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- 0.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth
Rapid sales growth shows that Kuros is expanding adoption of its bone-healing products across targeted surgical markets. Continued revenue scale can improve commercial leverage, support investment in capacity, and strengthen the platform for sustained earnings growth.
High Gross Margins
The high gross margin indicates substantial economic value in the product portfolio and provides room to absorb commercialization and development costs. As revenue scales, this margin structure can support operating leverage and a more durable path to profitability.
Commercial And Clinical Traction
Broader distributor reach, rising surgeon utilization, and substantial patient experience indicate strengthening commercial traction rather than isolated product demand. Ongoing clinical studies and published outcomes could further support adoption, institutional confidence, and market-share expansion.
Bears Say
Weak Cash Conversion
Cash generation has lagged the recent earnings improvement, with operating and free cash flow turning negative. If this persists, working-capital needs and investment spending could increase funding sensitivity and constrain the company’s ability to finance growth internally.
Near-Term Margin Pressure
The planned U.S. production ramp and continuing transformation spending may temporarily offset the benefits of scale and operating leverage. This creates execution risk around the timing of margin expansion, particularly while the company is still establishing consistent profitability.
Clinical Evidence Still Developing
Important comparative clinical evidence is still being generated, so the full support for broader claims, payer acceptance, and institutional adoption has not yet been established. Delayed or less supportive results could limit the pace of expansion in new indications.
Kuros Biosciences News
Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion
Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Study Overview: Kuros Biosciences is conducting a prospective, randomized, multi-center study titled A Prospective, Randomized, Multi-Center Study to Assess
Kuros Biosciences’ Clinical Study on MagnetOs Flex Matrix: A Potential Game-Changer in Spinal Fusion
Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Kuros Biosciences is conducting a phase IV post-marketing study titled A Prospective, Randomized, Multi-center Study to Assess the Performance
0RHR FAQ
What was Kuros Biosciences’s price range in the past 12 months?
What is Kuros Biosciences’s market cap?
When is Kuros Biosciences’s upcoming earnings report date?
How were Kuros Biosciences’s earnings last quarter?
Is Kuros Biosciences overvalued?
Does Kuros Biosciences pay dividends?
What is Kuros Biosciences’s EPS estimate?
How many shares outstanding does Kuros Biosciences have?
What happened to Kuros Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kuros Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Kuros Biosciences
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Christopher T. Fair
- Employees
- 213
- Website
- kurosbio.com
- Address
- Wagistrasse 25, Schlieren, ZH, 8952, CH
Kuros Biosciences (0RHR) Earnings & Revenues
0RHR Company Deck
0RHR Earnings Call
Earnings Call SentimentPositive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.
View all GB:0RHR earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |












